HOOK Insider Trading

Insider Ownership Percentage: 3.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Hookipa Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Hookipa Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Hookipa Pharma Share Price & Price History

Current Price: $1.95
Price Change: Price Increase of +0.01 (0.52%)
As of 01/17/2025 05:00 PM ET

This chart shows the closing price history over time for HOOK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$1.95Closing price on 01/19/25:

Hookipa Pharma Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Hookipa Pharma (NASDAQ:HOOK)

63.88% of Hookipa Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HOOK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$103kbought$34MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$20M$0$20MTotal InflowsTotal Outflows
Hookipa Pharma logo
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More on Hookipa Pharma

Today's Range

Now: $1.95
Low: $1.90
High: $2.01

50 Day Range

MA: $2.29
Low: $1.78
High: $3.70

52 Week Range

Now: $1.95
Low: $1.72
High: $10.50

Volume

78,179 shs

Average Volume

95,853 shs

Market Capitalization

$23.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Who are the company insiders with the largest holdings of Hookipa Pharma?

Hookipa Pharma's top insider shareholders include:
  1. Jorn Aldag (CEO)
  2. Reinhard Kandera (CFO)
Learn More about top insider investors at Hookipa Pharma.